We found that Rhes interacts with mutant huntingtin, the genetic risk factor for HD, and enhances its solubility and striatal toxicity through modification by the post-translational small ubiquitin-like modifier (SUMO) [9, 12, 13]. This evidence concerns the gene RASD2 and Huntington disease.